PD 173074: Selective FGFR1 Inhibitor for FGFR Signaling Pathway Research

Executive Summary: PD 173074 (CAS 219580-11-7) is a small molecule inhibitor with high selectivity for FGFR1 tyrosine kinase (IC₅₀ ≈ 25 nM in enzymatic assays) and moderate activity against VEGFR2 (IC₅₀ 100–200 nM) [1]. The compound exhibits approximately 1000-fold selectivity for FGFR1 compared to kinases such as c-Src and PDGFR [2]. PD 173074 blocks FGFR-driven signaling by inhibiting receptor autophosphorylation, reducing proliferation in FGFR-dependent cell lines [1]. Molecular docking studies confirm strong binding of PD 173074 to FGFR1 (binding energy −8.14 kcal/mol) [1]. APExBIO’s validated PD 173074 (A8253) supports reproducible FGFR pathway studies in cancer and neuropsychiatric research [2].

Biological Rationale

Fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases critical for cell proliferation, differentiation, and angiogenesis. Dysregulation of FGFR signaling is implicated in oncogenesis and neurodevelopmental disorders including schizophrenia [1]. Recent phenome-wide association and Mendelian randomization studies identify FGFR1 as a druggable target with significant association to schizophrenia pathogenesis [1]. Selective inhibition of FGFR1 provides a mechanistic tool to validate its role in disease models and to profile FGFR-driven cellular outcomes. PD 173074’s specificity enables distinction between FGFR, VEGFR, and off-target kinase signaling.

Mechanism of Action of PD 173074

PD 173074 competitively inhibits the ATP-binding site of FGFR1, blocking receptor autophosphorylation and downstream signaling. In enzymatic assays using purified FGFR proteins, PD 173074 exhibits an IC₅₀ of 25 nM for FGFR1 and 100–200 nM for VEGFR2 [2]. The compound demonstrates ~1000-fold selectivity for FGFR1 over kinases such as c-Src and PDGFR. In cell-based assays, it suppresses FGFR-dependent cell proliferation and viability, with negligible activity in non-FGFR–driven cell lines. PD 173074 also inhibits FGFR signaling-induced angiogenesis in vivo at 1–2 mg/kg/day (intraperitoneal, Swiss Webster mice) without overt toxicity [2]. Molecular docking confirms strong binding affinity (−8.14 kcal/mol) for the FGFR1 active site [1].

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 tyrosine kinase activity with an IC₅₀ of approximately 25 nM in enzymatic assays (Molecular Neurobiology 2025, DOI).
• VEGFR2 is inhibited by PD 173074 at IC₅₀ values ranging from 100–200 nM, indicating moderate cross-reactivity (APExBIO).
• The inhibitor displays about 1000-fold selectivity for FGFR1 over c-Src and PDGFR at comparable conditions (APExBIO).
• Molecular docking studies show strong binding of PD 173074 to FGFR1 (binding energy −8.1407 kcal/mol) (DOI).
• In vivo, PD 173074 inhibits FGF- and VEGF-induced angiogenesis in Swiss Webster mice at 1–2 mg/kg/day without significant toxicity (APExBIO).
• FGFR1 is predominantly expressed in mural cells, supporting the rationale for selective FGFR1 inhibition in neuropsychiatric and cancer research (DOI).

This article extends the mechanistic detail and neuropsychiatric context compared to the scenario-driven protocols in this PD 173074 workflow guide, which focuses on experimental reproducibility. For an in-depth look at advanced cancer applications, see this cancer research article; here, we clarify the selectivity and neurodevelopmental relevance of PD 173074. For protocol-specific guidance and experimental troubleshooting, refer to this scenario-based methods article.

Applications, Limits & Misconceptions

PD 173074 is widely used in:

• Target validation for FGFR1-driven cancer research and drug discovery.
• Screening and mechanistic studies in cell lines with FGFR-dependent proliferation.
• Angiogenesis inhibition assays (both in vitro and in vivo models).
• Neuropsychiatric research, notably in schizophrenia models, due to FGFR1’s genetic association with disease risk (DOI).

Common Pitfalls or Misconceptions

• Not a pan-FGFR inhibitor: PD 173074 is selective for FGFR1 and less effective against FGFR2/3/4, requiring careful target validation.
• Limited water solubility: The compound is insoluble in water; use DMSO (≥26.18 mg/mL) or ethanol (≥108.4 mg/mL with sonication) for stock solutions (APExBIO).
• Storage constraints: Solutions should be used promptly; long-term storage above −20°C may degrade activity (APExBIO).
• Not suitable for non-FGFR–driven models: Ineffective in cell lines or systems lacking active FGFR signaling.
• Off-target effects at high doses: At micromolar concentrations, cross-inhibition of VEGFR2 or other kinases may occur.

Workflow Integration & Parameters

Preparation: Dissolve PD 173074 in DMSO or ethanol, ensuring complete dissolution (sonication may be required for ethanol). Prepare fresh working solutions immediately before use. Store powder at 4°C; stock solutions at −20°C for up to several months.

Assay design: Use nanomolar to low micromolar concentrations for cell-based assays. Include vehicle controls and parallel non-FGFR–dependent lines as negative controls.

Animal studies: Administer 1–2 mg/kg/day intraperitoneally in Swiss Webster mice for in vivo angiogenesis models (no overt toxicity observed in published studies).

For protocol optimization and troubleshooting, see this detailed guide on FGFR1 inhibition; this article clarifies the storage, solubility, and selectivity boundaries of PD 173074 (A8253) compared to broader kinase inhibitors.

Conclusion & Outlook

PD 173074 is a validated, highly selective FGFR1 inhibitor supporting mechanistic studies in oncology and neuropsychiatry. Its reproducibility, selectivity, and strong molecular docking profile make it a reference compound for FGFR pathway research. Emerging genetic and molecular evidence positions FGFR1 inhibition as a promising strategy in schizophrenia and other disorders. For reliable FGFR pathway inhibition, the APExBIO PD 173074 (A8253) kit is recommended for research use.